Literature DB >> 20824002

Clinical Experience with Lapatinib in Patients with ErbB2-Overexpressing Metastatic Breast Cancer.

Nadia Harbeck1, Volker Heinemann, Sibylle Loibl, Michael Untch.   

Abstract

Entities:  

Year:  2008        PMID： 20824002      PMCID： PMC2930990          DOI： 10.1159/000119744

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


× No keyword cloud information.
  32 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 2.  Blood-brain barrier delivery.

Authors:  William M Pardridge
Journal:  Drug Discov Today       Date:  2006-11-13       Impact factor: 7.851

Review 3.  EGFR and cancer prognosis.

Authors:  R I Nicholson; J M Gee; M E Harper
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

4.  The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.

Authors:  D W Rusnak; K Affleck; S G Cockerill; C Stubberfield; R Harris; M Page; K J Smith; S B Guntrip; M C Carter; R J Shaw; A Jowett; J Stables; P Topley; E R Wood; P S Brignola; S H Kadwell; B R Reep; R J Mullin; K J Alligood; B R Keith; R M Crosby; D M Murray; W B Knight; T M Gilmer; K Lackey
Journal:  Cancer Res       Date:  2001-10-01       Impact factor: 12.701

Review 5.  Growth factor receptors in breast cancer: potential for therapeutic intervention.

Authors:  Rita Nahta; Gabriel N Hortobágyi; Francisco J Esteva
Journal:  Oncologist       Date:  2003

6.  NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer.

Authors:  T A Christianson; J K Doherty; Y J Lin; E E Ramsey; R Holmes; E J Keenan; G M Clinton
Journal:  Cancer Res       Date:  1998-11-15       Impact factor: 12.701

7.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

8.  Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.

Authors:  Wenle Xia; Lei-Hua Liu; Peter Ho; Neil L Spector
Journal:  Oncogene       Date:  2004-01-22       Impact factor: 9.867

9.  Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

Authors:  Johanna C Bendell; Susan M Domchek; Harold J Burstein; Lyndsay Harris; Jerry Younger; Irene Kuter; Craig Bunnell; Montse Rue; Rebecca Gelman; Eric Winer
Journal:  Cancer       Date:  2003-06-15       Impact factor: 6.860

10.  A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Authors:  David Cameron; Michelle Casey; Michael Press; Deborah Lindquist; Tadeusz Pienkowski; C Gilles Romieu; Stephen Chan; Agnieszka Jagiello-Gruszfeld; Bella Kaufman; John Crown; Arlene Chan; Mario Campone; Patrice Viens; Neville Davidson; Vera Gorbounova; Johannes Isaac Raats; Dimosthenis Skarlos; Beth Newstat; Debasish Roychowdhury; Paolo Paoletti; Cristina Oliva; Stephen Rubin; Steven Stein; Charles E Geyer
Journal:  Breast Cancer Res Treat       Date:  2008-01-11       Impact factor: 4.872
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.